- Home
- ASGN vs AMLX Comparison
ASGN vs AMLX Comparison
Compare ASGN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASGN | AMLX |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASGN | AMLX |
|---|---|---|
| Price | $38.46 | $16.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $51.20 | $20.11 |
| AVG Volume (30 Days) | 653.6K | ★ 872.5K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 2.60 | N/A |
| Revenue | ★ $3,980,400,000.00 | $380,786,000.00 |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $14.77 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $34.59 | $3.11 |
| 52 Week High | $62.42 | $17.49 |
Technical Indicators
Market Signals| Indicator | ASGN | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 65.11 |
| Support Level | $34.59 | $12.29 |
| Resistance Level | $40.16 | $17.22 |
| Average True Range (ATR) | 1.69 | 0.81 |
| MACD | 0.44 | 0.26 |
| Stochastic Oscillator | 71.36 | 96.55 |
Price Performance
Historical ComparisonAbout ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.